Team:Glasgow/PathwayTools/Pathways

From 2011.igem.org

(Difference between revisions)
(Created page with "{{Team:Glasgow/Header}} <h1>Pathways</h1> <h2>Improving the Carotenoid Pathway</h2> In 2009 the <a href=https://2009.igem.org/Team:Cambridge>Cambridge iGEM team</a> submitted a...")
 
(31 intermediate revisions not shown)
Line 1: Line 1:
{{Team:Glasgow/Header}}
{{Team:Glasgow/Header}}
-
 
+
<HTML>
-
<h1>Pathways</h1>
+
<h1>Modular Product Synthesis Pathways</h1>
 +
<h6><a href="https://2011.igem.org/Team:Glasgow/Results">Back to Results</a></h6>
<h2>Improving the Carotenoid Pathway</h2>
<h2>Improving the Carotenoid Pathway</h2>
-
In 2009 the <a href=https://2009.igem.org/Team:Cambridge>Cambridge iGEM team</a> submitted a number of biobricks associated with the carotenoid pathway.<br/>
+
<table>
-
We have been working with these to prove the principle of light controlled manufacturing.<br/><br/>To improve this pathway, we have had the crtY gene synthesized.<Br/><br/>
+
<tr>
-
 
+
<td>
 +
In 2009 the <a href=https://2009.igem.org/Team:Cambridge>Cambridge iGEM team</a> submitted a number of biobricks associated with the carotenoid pathway. These included the biobrick <a href="http://partsregistry.org/wiki/index.php/Part:BBa_K274100">BBa_K274100</a> that converts FPP to to the red coloured lycopene. Lycopene is usually converted to the orange colour carotenoid β-carotene although the enzyme, crtY, although the gene for this enzyme not included in the <a href="http://partsregistry.org/wiki/index.php/Part:BBa_K274100">BBa_K274100</a> biobrick so only lycopene is produced. The team also created the <a href=http://partsregistry.org/wiki/index.php/Part:BBa_K274200>BBa_K274200</a> biobrick which includes the whole enzymatic pathway resulting in β-carotene.<br/></br>
 +
We have been working with these carotenoid biobricks to prove the principle of light controlled manufacturing. We used <a href="http://partsregistry.org/wiki/index.php/Part:BBa_K274100">BBa_K274100</a> to produce lycopene under control of a light dependant promoter. Using another light dependant promoter it would be possible trigger the expression of just the CrtY gene to selectively convert the lycopene into β-carotene.</br></br>
 +
The 2009 Cambridge iGEM team did not include a biobrick of just this step in the pathway so we amplified it using PCR and added biobrick ends. This pathway could now be controlled by light, to determine which product is synthesised.<br/><br/>
 +
<Br/><br/><Br/><br/><Br/><br/><Br/><br/><Br/><br/><Br/><br/>
 +
</td>
 +
<td>
 +
<img src="https://static.igem.org/mediawiki/2011/d/db/Carotinoidpathwayglasgow.jpg" width="500"/></br>
 +
<b>Figure 1: β-carotene synthesis pathway.</b> This figure shows how the simple molecule IPP is converted to β-carotene through a number of enzyme catalyse reactions. Image from Beyer et al, 2002 "Golden Rice: Introducing the ß-Carotene Biosynthesis Pathway into Rice Endosperm by Genetic Engineering to Defeat Vitamin A Deficiency"  The American Society for Nutritional Sciences J. Nutr. 132:506S-510S.
 +
</td>
 +
</tr>
 +
</table>
<table border="1" width="890px">
<table border="1" width="890px">
<tr>
<tr>
Line 19: Line 31:
</tr>
</tr>
</table>
</table>
 +
 +
<h2>Opiates Pathway</h2>
 +
 +
<p>This system of light controlled product selection can be applied other metabolic pathways to create useful products from a common precursor. The therapeutically useful derivatives of morphine is would work well with this system allowing the light based selection of a number of products from a common precursor. These compounds all analgesics have a similar structure but have a wide range of uses. Morphine is a very powerful analgesic as is heroin both controlled substances but another member codeine is available to buy in most countries as a weak analgesic (pain relief), an antitussive (cough medicine) and an antidiarrheal (diarrhoea treatment.</br> 
 +
 +
<img src="https://static.igem.org/mediawiki/2011/5/5c/Opiatespathway.jpg" width="100%" /></br>
 +
<b>Figure 2: Therapeutically useful morphine derivatives.</b> Although these molecules have a very similar structure they can have a wide range of uses.
 +
 +
<h2>References</h2>
 +
<p>Bruce NC, et al "Engineering pathways for transformations of morphine alkaloids", TIBTECH, June 1995, Vol 13.
 +
<p>Beyer et al, 2002 "Golden Rice: Introducing the ß-Carotene Biosynthesis Pathway into Rice Endosperm by Genetic Engineering to Defeat Vitamin A Deficiency"  The American Society for Nutritional Sciences J. Nutr. 132:506S-510S.
 +
 +
 +
</html>

Latest revision as of 03:51, 22 September 2011

Modular Product Synthesis Pathways

Back to Results

Improving the Carotenoid Pathway

In 2009 the Cambridge iGEM team submitted a number of biobricks associated with the carotenoid pathway. These included the biobrick BBa_K274100 that converts FPP to to the red coloured lycopene. Lycopene is usually converted to the orange colour carotenoid β-carotene although the enzyme, crtY, although the gene for this enzyme not included in the BBa_K274100 biobrick so only lycopene is produced. The team also created the BBa_K274200 biobrick which includes the whole enzymatic pathway resulting in β-carotene.

We have been working with these carotenoid biobricks to prove the principle of light controlled manufacturing. We used BBa_K274100 to produce lycopene under control of a light dependant promoter. Using another light dependant promoter it would be possible trigger the expression of just the CrtY gene to selectively convert the lycopene into β-carotene.

The 2009 Cambridge iGEM team did not include a biobrick of just this step in the pathway so we amplified it using PCR and added biobrick ends. This pathway could now be controlled by light, to determine which product is synthesised.
Figure 1: β-carotene synthesis pathway. This figure shows how the simple molecule IPP is converted to β-carotene through a number of enzyme catalyse reactions. Image from Beyer et al, 2002 "Golden Rice: Introducing the ß-Carotene Biosynthesis Pathway into Rice Endosperm by Genetic Engineering to Defeat Vitamin A Deficiency" The American Society for Nutritional Sciences J. Nutr. 132:506S-510S.
Forward Primer 5' - GAATTCGCGGCCGCTTCTAGAGAGGAGGATTACAAAATGCAACGCATTATGATCTGATTCTCG-3'
Reverse Primer 5'-TGCAGCGGCCGCTACTAGTATTATTAACGATGAGTCGTCATAATGGCTTGC-3'

Opiates Pathway

This system of light controlled product selection can be applied other metabolic pathways to create useful products from a common precursor. The therapeutically useful derivatives of morphine is would work well with this system allowing the light based selection of a number of products from a common precursor. These compounds all analgesics have a similar structure but have a wide range of uses. Morphine is a very powerful analgesic as is heroin both controlled substances but another member codeine is available to buy in most countries as a weak analgesic (pain relief), an antitussive (cough medicine) and an antidiarrheal (diarrhoea treatment.

Figure 2: Therapeutically useful morphine derivatives. Although these molecules have a very similar structure they can have a wide range of uses.

References

Bruce NC, et al "Engineering pathways for transformations of morphine alkaloids", TIBTECH, June 1995, Vol 13.

Beyer et al, 2002 "Golden Rice: Introducing the ß-Carotene Biosynthesis Pathway into Rice Endosperm by Genetic Engineering to Defeat Vitamin A Deficiency" The American Society for Nutritional Sciences J. Nutr. 132:506S-510S.

Retrieved from "http://2011.igem.org/Team:Glasgow/PathwayTools/Pathways"